Sanofi Confident In Beyfortus Achieving Blockbuster Status In 2024

Foresees Strength Versus Future RSV Antibody Competitor

 
• By Mandy Jackson

Beyfortus was a minimal contributor in Sanofi’s second quarter, which beat consensus and prompted an earnings guidance boost, but the RSV antibody’s sales should surge in Q3 and Q4.

Sanofi logo at a skyscraper in Warsaw, Poland
Beyfortus and Dupixent bookended Sanofi's sales in terms of lowest and highest sellers in Q2 • Source: Shutterstock

More from New Products

More from Scrip